Beta-Dexolone

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beta-Dexolone

Quick Facts

Property Description
Active ingredient Betamethasone Dipropionate
Form Topical Preparation (e.g., Cream, Ointment, Lotion)
Pharmacological class High-Potency Glucocorticoid / Corticosteroid
General use Relief from acute inflammatory skin symptoms
Origin Synthetic Derivative

1. Defining Beta-Dexolone: A High-Potency Corticosteroid

Beta-Dexolone is a pharmaceutical preparation that contains the active ingredient Betamethasone Dipropionate, classifying it as a Topical Corticosteroid of high potency, designed exclusively for application on the skin. This active substance is a synthetic derivative belonging to the Glucocorticoids pharmacological class. As a potent corticosteroid, this molecule possesses a substantial anti-inflammatory capacity, characterizing its therapeutic function within the wider family of corticosteroids. The high-potency status of Betamethasone Dipropionate places it among the more concentrated steroid options available for cutaneous treatment.

2. Composition and Topical Application of Beta-Dexolone

The medicine is formulated for Topical (cutaneous) use, as a single-entity dermatological product. Beta-Dexolone contains the active ingredient Betamethasone Dipropionate integrated within a Dermatological vehicle, which may be a cream, ointment, or lotion base. This route of administration is designed so that the effects of the active ingredient are concentrated locally within the skin's layers where inflammation is present. The formulation strategy utilizes the topical form to apply the medication directly to the affected skin area while limiting broader systemic exposure.

3. General Therapeutic Role of Beta-Dexolone

The general purpose of Beta-Dexolone is to provide relief from severe inflammatory skin conditions through its Anti-inflammatory and localized Immunosuppressive actions. In cases where a skin rash involves significant thickening and inflammation, the preparation's strength is utilized to facilitate a resolution of symptoms. By modulating the immune response within the skin, the medication addresses the discomfort associated with intense inflammation. Its use is intended to calm aggravated areas by reducing symptoms such as severe itching (pruritus), excessive redness (erythema), and swelling (edema).

Regulatory References

  1. MedlinePlus: Steroids

What side effects are possible with Beta-Dexolone?

Possible Side Effects and Safety Information

The safety profile of Beta-Dexolone is officially documented based on regulatory authority classifications, detailing potential adverse reactions and use restrictions.

Adverse Reactions by Body System

Adverse reactions are grouped by the major systems they affect, which include Endocrine, Metabolic/Fluid and Electrolyte, Gastrointestinal, Musculoskeletal, Neurological/Psychiatric, and Ophthalmic disorders. Common effects can include increased blood pressure, weight gain, and changes in mood. Serious reactions, some of which are documented as rare or with unknown frequency, encompass conditions such as adrenal insufficiency, cataracts, glaucoma, gastrointestinal perforation, and severe mood disturbances (including psychosis).

Risk Patterns and Restrictions

Dose and Duration: The risk of clinically significant adverse effects, such as the development of Cushing's syndrome, bone weakening (osteoporosis), and suppression of growth in children, generally increases with higher doses and prolonged use. Abrupt discontinuation of the medicine after extended therapy can lead to withdrawal symptoms, including acute adrenal insufficiency.

Population Considerations: Specific safety considerations are documented for certain populations. For example, reduced growth rates have been observed in children receiving long-term treatment, and use during pregnancy is associated with a risk of fetal harm. Caution and appropriate monitoring are required in the elderly and those with underlying conditions like diabetes, hypertension, or a history of tuberculosis.

Restrictions: Beta-Dexolone is formally contraindicated (should not be used) in patients with systemic fungal infections and those with a known severe allergy to the medicine. Official documentation mandates careful monitoring when used in patients with certain pre-existing conditions, as the drug can mask signs of infection or worsen conditions like ocular herpes simplex.

Overdose and Emergency Response

Overdose Manifestations and Systemic Risk

Overdose of Beta-Dexolone (Betamethasone Dipropionate) is primarily a concern for systemic toxicity resulting from excessive absorption through the skin. This typically occurs following prolonged use, application over large body surface areas, or the use of occlusive dressings. Systemic absorption may lead to signs consistent with Cushing's syndrome and laboratory evidence of reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. Other documented metabolic manifestations include hyperglycemia (high blood sugar) and glucosuria (sugar in the urine).

When to Seek Urgent Medical Help

Urgent medical evaluation is required if signs of excessive systemic exposure or adrenal insufficiency are suspected. The regulatory focus is on managing potential adrenal crisis; therefore, consultation is necessary to initiate a gradual withdrawal of the topical corticosteroid or to substitute it with a lower-potency agent. Monitoring of the HPA axis function is mandatory in cases of confirmed suppression.

Population-Specific Considerations

Official regulatory labeling notes that pediatric patients are at significantly greater risk for systemic toxicity due to their higher skin surface area-to-body weight ratio. Specific serious manifestations documented in children include intracranial hypertension (which may present as headaches or bulging fontanelles) and inhibition of growth, such as linear growth retardation and delayed weight gain. No specific antidote for systemic overdose is known; management focuses entirely on supportive care.

Therapeutic Uses of Beta-Dexolone

What Beta-Dexolone Treats: Main Uses and Benefits

Beta-Dexolone is applicable in the symptomatic management of dermatological conditions characterized by acute and often severe inflammation. The medication is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.


Targeting Severe and Resistant Skin Conditions

This high-potency agent is relevant in therapeutic domains where conditions like severe plaque psoriasis, highly resistant atopic dermatitis or eczema, and Lichen Simplex Chronicus are present. The preparation is relevant for easing symptoms of intense, chronic inflammation associated with these conditions, including persistent skin thickening, scaling, and the formation of hardened plaques. This focused symptomatic support may assist with managing acute episodes and supports maintaining a sense of stability when symptoms are more noticeable.

Symptom Relief for Intense Flare-ups

Beta-Dexolone is applied to address acute episodes and flare-ups marked by high-intensity symptoms. It helps manage the distressing clusters of excessive redness (erythema), localized swelling (edema), and severe itching (pruritus). This focused symptomatic support is also considered relevant for localized, stubborn symptomatic manifestations, particularly in areas like the palms, soles, or the scalp, which often present with symptoms that are more difficult to ease. When applied in these contexts, it offers supportive relief that helps ease the overall symptom burden and may contribute to improved comfort during symptomatic periods.


Quick Fact Block

Quick Fact Description
Relief for Symptoms of severe inflammation, intense itching (pruritus), skin thickening (lichenification), and excessive scaling.
Context Applied during acute flare-ups of chronic conditions or in cases resistant to milder symptomatic support.
Main Benefit Provides support that helps ease the overall symptom load and assists with maintaining functional stability.

Regulatory References

  1. NIH DailyMed label for Betamethasone Dipropionate

Eligibility and Restrictions for Use

Who Can and Cannot Use Beta-Dexolone?

Eligibility for Beta-Dexolone (Betamethasone Dipropionate) is determined by official regulatory guidelines, focusing on specific age groups, medical history, and pre-existing conditions.


Populations and Conditions for Exclusion

Category Regulatory Status & Practical Implication
Absolute Contraindications Use is prohibited for individuals with known hypersensitivity to the active ingredient or any component, and for those with rosacea, perioral dermatitis, or untreated cutaneous infections [DailyMed/SmPC].
Age Restrictions The medicine is approved for patients 13 years of age and older. Use is not recommended for children younger than 13 and is generally contraindicated in infants under 1 year of age [DailyMed/SmPC].
Pregnancy and Lactation Use during pregnancy (Category C) is conditional and requires a careful risk assessment, to be used only if the potential benefit justifies the risk. Caution is advised for nursing mothers [DailyMed].
Conditional Use Caution is required for patients with comorbidities like liver failure or conditions such as glaucoma or Cushing’s syndrome due to the increased risk of systemic absorption [FDA Label].

These official rules strictly define the eligible population for this high-potency topical corticosteroid, excluding those with high-risk conditions or those below the approved age threshold.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interaction patterns for Beta-Dexolone, a high-potency topical corticosteroid, strictly based on official regulatory documentation.

Primary Interaction Profile: Additive Glucocorticoid Exposure

Regulatory information emphasizes the risk of a pharmacodynamic interaction stemming from the potential for percutaneous absorption. Co-administration of Beta-Dexolone with any other medicinal product containing a corticosteroid is officially documented as increasing the patient's total systemic glucocorticoid exposure. This additive effect heightens the documented risk for developing systemic effects, such as the suppression of the hypothalamic-pituitary-adrenal (HPA) axis.

Interaction Type Interacting Substance/Condition Officially Documented Effect
Pharmacodynamic Other Corticosteroid-Containing Products Increases total systemic glucocorticoid exposure
Population Risk Liver Failure (Hepatic Impairment) Predisposes to increased systemic effects

Absence of Specific Drug-Drug Interactions

Official regulatory labels for this topical preparation do not list specific metabolic, transporter-mediated, or classic drug-drug interactions, such as those involving CYP enzymes. Furthermore, no mandatory timing separation rules are documented for co-administration. There are also no officially documented interactions with food, alcohol, or herbal supplements.

Population-Dependent Exposure Risk

The regulatory profile formally notes that patient factors, such as pre-existing liver failure, increase a person's predisposition to the systemic effects resulting from potential exposure. This consideration highlights a population-specific context where the risk of total systemic exposure is heightened.

Mechanism of Action

The mechanism initiates when the active ingredient binds to the intracellular Glucocorticoid Receptor (GR). This activated complex primarily engages in Transrepression, physically binding to and inactivating key inflammatory transcription factors like NF-κB. By modulating the cell's gene expression, the drug decreases the transcription of inflammatory proteins such as cytokines, regulating immune signaling at the cellular level.

The drug also works by inducing the synthesis of Annexin A1, a protein that blocks the enzyme Phospholipase A2 (PLA2). This action halts the entire Arachidonic Acid Cascade, preventing the formation of all potent lipid mediators, including prostaglandins and leukotrienes. This blockade eliminates the chemical signals that mediate vascular leakage and nociceptor sensitization.

Beyond genomic modulation, the mechanism includes a rapid physical effect: direct vasoconstriction at the application site. This action, combined with reduced signaling for immune cell adhesion, limits local blood flow and capillary permeability. This simultaneous physical and chemical restraint leads to a physiological decrease in vascular permeability and local blood flow, restricting the infiltration of immune cells and plasma into the affected tissue.

Dosage and Administration Information

Beta-Dexolone is designated for topical (cutaneous) administration only, utilizing formulations such as a cream, ointment, lotion, or gel at a concentration of 0.05% of the active ingredient. The medicine is applied as a thin film gently rubbed into the affected skin area, typically once daily or twice daily as determined by a healthcare provider. Standard application parameters define the total amount and duration of therapy to maintain control over systemic exposure.

Application must not exceed 50 grams per week, and continuous treatment is generally limited to no more than two consecutive weeks. Therapy should be discontinued promptly once control of the condition is achieved. If no improvement is observed within two weeks, a re-evaluation of the diagnosis is typically indicated.

Several specific procedural constraints are outlined to ensure proper use. The medicine must not be used on the face, groin, or axillae (underarms), and it is crucial to avoid covering the treated area with occlusive dressings (bandages or wraps) unless specifically instructed. After each application, hands must be thoroughly washed. Regarding specific populations, the augmented 0.05% formulations are not recommended for use in patients under 13 years of age, establishing a clear age-related constraint for its administration.

Recent Clinical Evidence

Beta-Dexolone: Recent Clinical Evidence

Evidence for Core Corticosteroid-Responsive Dermatoses

The research on Beta-Dexolone has been conducted for conditions where the skin experiences inflammation, such as severe plaque psoriasis and certain eczematous disorders. The most common type of research involves Randomized Controlled Trials (RCTs), where the medicine was evaluated against an inactive vehicle (placebo) to explore symptom patterns. The studies monitored outcomes related to inflammatory or irritative states, such as the intensity of itching (pruritus), redness (erythema), and scaling. Findings describe patterns observed in the studies, and systematic reviews and meta-analyses were evaluated in peer-reviewed scientific literature, contributing to the broader evidence landscape.

Research on Long-Term Follow-up and Maintenance

The follow-up durations for many of the core clinical evaluations were limited, with the majority of research exploring short-term symptom changes, typically over two to four weeks. While some studies monitored responses over slightly longer defined time intervals, there is limited information for long-term outcomes and the sustained management of symptoms. Long-term effects are not fully established, and data show patterns related to maintenance use are still emerging.

Evidence in Special Populations

The initial body of research largely focused on Adults with moderate to severe skin conditions. Studies have also explored the use of the medicine in specific populations, including adolescents and children (aged two years and older). However, data for certain groups remain insufficient; the results apply mainly to the populations studied.

Research Gaps and Unanswered Questions

Scientific summaries of the research identify several areas where data remain insufficient or uncertain. A key limitation noted is the short duration of most studies. Another key research limitation is the absence of comprehensive data related to the impact on patient-reported outcomes, such as quality of life (QoL). Comparative evidence is also lacking in some therapeutic areas. The evidence highlights what is known and what is still uncertain; research provides context but not individual predictions.

Key Studies & References

  1. Betamethasone Dipropionate Ointment, Cream, Lotion, and Spray (Official FDA/DailyMed Labeling)

Frequently Asked Questions (FAQ)

Common questions about Beta-Dexolone (FAQ)


Q: How long does it typically take to feel the effects of Beta-Dexolone?

According to the official product information, patients often notice some improvement in their skin condition within the first few days of starting treatment. For many conditions, improvements are typically noted within three to four days, with resolution or significant improvement typically observed within one week in clinical studies.

Q: If I stop taking Beta-Dexolone suddenly, what kind of withdrawal effects are possible?

The sudden discontinuation of topical corticosteroids can sometimes lead to what is known as Topical Steroid Withdrawal (TSW). Reported symptoms can include increased redness, a burning or stinging sensation, swelling, and increased skin sensitivity in the treated areas. These reactions may occur days to weeks after stopping the medication.

Q: Is it common to feel unusually tired or weak when starting Beta-Dexolone?

Regulatory documents list unusual tiredness or weakness as a symptom that should be reported to a healthcare provider. These are potential, though rare, signs of systemic absorption effects, such as the suppression of the adrenal glands. Monitoring for these symptoms may be conducted as part of the treatment protocol.

Q: Is it normal to have a change in heart rate while on Beta-Dexolone?

A fast, irregular, or pounding heartbeat is listed in official product safety information as a symptom to be aware of and report to your healthcare provider. This can be an indication that the active ingredient is being absorbed systemically, affecting the body beyond the application site.

Q: Is Beta-Dexolone used for conditions beyond inflammation and immune response?

Official regulatory summaries state that the active ingredient is formally indicated to relieve the itching and inflammatory symptoms of corticosteroid-responsive dermatoses. This means its primary role is specifically focused on skin conditions that respond to strong steroids, rather than treating internal conditions.

Q: Does Beta-Dexolone interact with common pain relievers like ibuprofen or aspirin?

While regulatory labels do not list mandatory timing separation rules, they do note that there is a potential for moderate drug interactions with certain pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen or aspirin. Discussion of all current medications with a healthcare professional is advisable.

Q: Is it better to take Beta-Dexolone in the morning or at night?

The recommended timing depends on the specific formulation being used. Official dosing instructions for the lotion formulation, for instance, often direct application twice daily, once in the morning and once at night. For other forms, frequency of application is determined by the healthcare provider.

Q: Are there any specific dietary restrictions to follow while on Beta-Dexolone?

Regulatory labels explicitly state that there are no officially documented interactions with food or herbal supplements for this topical medication. This means there is no need for specific dietary restrictions because of this medicine.

Q: Is there a non-oral (e.g., topical or injectable) form of Beta-Dexolone available?

Beta-Dexolone itself is strictly formulated as a topical product, such as an ointment, cream, or lotion. However, the systemic form of the active ingredient (Betamethasone) is available in other formulations, including a suspension for injection, for use in different medical situations.

Q: Does Beta-Dexolone affect fertility or sexual function?

Official patient information from regulatory bodies states there is no evidence that Betamethasone skin treatments affect fertility in either men or women. Any concerns regarding sexual function can be addressed with a healthcare professional.

Q: Is Beta-Dexolone a drug that requires regular blood work monitoring?

Although it is a topical medicine, laboratory tests may sometimes be performed, especially if the medicine is used for extended periods or over large areas of the body. These tests, such as those that evaluate adrenal gland function, help check for any signs of systemic absorption.

Q: Can Beta-Dexolone be used for allergies or allergic reactions?

Yes, Betamethasone skin treatments are commonly used for inflammatory skin conditions like eczema and contact dermatitis. They work by stopping the release of chemicals that mediate inflammation and immune responses, which are often triggered by an allergic reaction or severe irritation.

Q: Can Beta-Dexolone cause skin changes like acne or easy bruising?

Official postmarketing reports have noted that local reactions in the skin can occur with topical corticosteroids. These reports include skin changes such as acne-like eruptions and thinning of the skin which can lead to easy bruising.

Q: Why do people sometimes experience stomach upset or heartburn on Beta-Dexolone?

Although this is a topical drug, systemic absorption can occur, meaning the medicine reaches the rest of the body. When systemic absorption happens, possible adverse reactions are listed that include nausea, indigestion, and stomach pain, which are related to upset stomach or heartburn.

Q: Is Beta-Dexolone known to cause or worsen existing depression?

Mood changes are a documented potential adverse reaction for this class of medicine. Symptoms such as depression or anxiety are listed as potential signs of Cushing’s syndrome, a rare adverse event that may occur due to systemic absorption of the steroid.

Q: What is the role of Beta-Dexolone in treating breathing problems like asthma or COPD?

The topical preparation of Beta-Dexolone is specifically indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive skin conditions. It is not indicated or approved for the treatment of internal breathing problems such as asthma or Chronic Obstructive Pulmonary Disease (COPD).

Q: What is the difference between Beta-Dexolone and other similar-sounding steroid drugs?

Beta-Dexolone contains Betamethasone Dipropionate, which is classified as a high-potency topical corticosteroid. This classification refers to its strength and ability to reduce inflammation on the skin compared to other steroid drugs, which may have different active ingredients or potency levels.

Q: Can Beta-Dexolone cause changes in appetite or lead to weight gain?

Yes, regulatory documents list weight gain as a potential side effect associated with the use of this medication. This effect, along with changes in appetite, is often related to the systemic absorption of the steroid, especially with prolonged or extensive use.

Q: Can taking Beta-Dexolone make other heart or blood pressure medicines less effective?

Beta-Dexolone has the potential to increase blood pressure, which is a documented common effect. This elevation in blood pressure can potentially complicate the management of pre-existing hypertension and requires caution if a patient is already taking blood pressure-lowering medication.

Q: What are the concerns about Beta-Dexolone and blood sugar levels?

Caution and careful monitoring are required when this medicine is used by patients with underlying conditions such as diabetes. Corticosteroids can affect blood sugar metabolism, and systemic absorption of the drug may impact the control of blood sugar levels.

Q: Do natural supplements, such as herbal remedies, interact with Beta-Dexolone?

Official regulatory labels for this topical preparation contain no documented interactions with food or herbal supplements. It is generally advisable to inform a healthcare professional about all supplements being taken.

Q: Is Beta-Dexolone safe to use while breastfeeding or pregnant?

The use during pregnancy is conditional, as documented under Pregnancy Category C, where the potential benefits must be determined to outweigh the potential risks. Caution is also advised for nursing mothers, as it is unknown if the drug is excreted in human milk in amounts that would affect the baby.

Q: Can Beta-Dexolone be used by children, and are there different concerns for them?

The medicine is approved for patients 13 years of age and older, and use is not recommended for younger children. Specific concerns for children include the risk of reduced growth rates and the suppression of the adrenal glands, especially with long-term treatment.

Q: What should I tell a surgeon or dentist if I am taking Beta-Dexolone?

Disclosure of all medications, including this one, to a surgeon or dentist is part of standard medical practice. This is due to the drug's potential to suppress the function of the adrenal glands, which is a factor to consider during surgical procedures or general anesthesia.

Q: What are the signs of the body's adrenal glands being suppressed by Beta-Dexolone?

Adrenal gland suppression (HPA axis suppression) is a documented risk of systemic exposure to corticosteroids. Signs to watch for and report may include unusual tiredness, weakness, dizziness, fainting, loss of appetite, and weight loss.

Q: Can Beta-Dexolone cause problems with vision or eye pressure (glaucoma)?

Yes, serious adverse reactions documented for the class of medicine include conditions affecting the eyes, such as cataracts and glaucoma (increased eye pressure). Patients with pre-existing glaucoma require caution and appropriate monitoring when using the medication.

Q: Can Beta-Dexolone affect bone density or increase the risk of osteoporosis?

The risk of bone weakening, or osteoporosis, is noted in the safety information for this medicine. This risk generally increases with the use of higher doses and for prolonged periods of time.

Q: Why might a doctor gradually lower the dose of Beta-Dexolone instead of stopping it immediately?

Abruptly stopping the medication after a course of extended therapy can lead to withdrawal symptoms, including a potentially serious condition called acute adrenal insufficiency. To prevent this, the dose may be gradually lowered (tapered) over time.

Q: Can Beta-Dexolone be used by patients with kidney or liver issues?

Official documentation notes that patient factors, such as pre-existing liver failure, increase a person's risk for systemic effects due to potential exposure. While liver issues are noted, specific guidance on the use of the topical medicine in patients with kidney problems is not documented.

How should Beta-Dexolone be stored and disposed of?

How to Store and Dispose of Beta-Dexolone

Storage and disposal requirements for Beta-Dexolone (Betamethasone Dipropionate topical) are strictly defined by regulatory labeling to maintain product stability and ensure household safety.

Official Storage Requirements

Requirement Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing, and protect from excess heat, moisture, and direct light.
Container Keep the medication in the original container and maintain it tightly closed.
Child Safety Keep the product out of the sight and reach of children.

Disposal

Disposal of any unused or expired product must be carried out according to local requirements and governmental guidelines. Unused medication should generally not be flushed down a toilet or sink unless specific label instructions state otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Beta-Dexolone found in:

A-Z Index: